World Hypertension Day’s Focus on High Blood Pressure Awareness, Management and Control Highlights Importance of New Therapies, like Ultrasound Renal Denervation
Paradise™ Ultrasound Renal Denervation (uRDN) system
Ultrasound Renal Denervation with the Paradise System
Palo Alto, CA, May 16, 2025 (GLOBE NEWSWIRE) — May 17, 2025, is World Hypertension Day, a day dedicated to raising awareness about high blood pressure, also known as the “silent killer” because many people do not know they have it and, over time, it can lead to serious health issues. The theme of World Hypertension Day, “Measure Your Blood Pressure Accurately, Control It, Live Longer!” highlights the importance of not only awareness but also accurate monitoring, diagnosis, and treatment of hypertension.
According to a report from the World Health Organization, the number of adults with hypertension doubled between 1990 and 2019 from 650 million to 1.3 billion. The report also states that only 54 percent of adults with hypertension are diagnosed and only 42 percent receive treatment. And recent studies1,2 have suggested that BP assessment in the clinical setting can often get a hypertension diagnosis wrong or miss it completely. Left undetected or uncontrolled, hypertension is a leading contributor to serious health risks, including heart attack, stroke and kidney disease, making accurate diagnosis, monitoring and treatment of the condition critical.
About one-third of the patients who are treated for hypertension remain uncontrolled despite making healthy lifestyle changes and taking more than three medications. For these patients, innovation and investment in new solutions are vital to achieve blood pressure control and realize a healthier future. From pharmaceutical treatments to technology, patients need new therapies that can provide life-changing results. This includes medical device-based therapies, like the Paradise™ Ultrasound Renal Denervation (uRDN) system, an additional treatment option for patients who remain uncontrolled and at elevated cardiovascular risk despite standard lifestyle changes and treatment with oral medications.
The Paradise uRDN system is a first-of-its-kind ultrasound-based RDN technology designed to lower blood pressure by denervating the sympathetic nerves surrounding the renal arteries, reducing the overactivity that can lead to hypertension. The Paradise uRDN system delivers two to three doses of 360-degree ultrasound energy — lasting seven seconds each — through the main renal arteries to the surrounding nerves.* The Paradise catheter features the exclusive HydroCooling™ system, which circulates sterile water through the balloon catheter during the procedure to help protect the renal artery wall. This minimally invasive procedure is supported by many medical societies including the American Heart Association, the American College of Cardiology, the European Society of Cardiology and others.
“Taking a risk-based approach to hypertension makes sense and this is why the medical societies are increasingly behind it,” said Prof. Andrew Sharp, University College Dublin and The Mater Misericordiae Hospital, Dublin, Ireland. “Blood pressure reductions of just 5 to 10mmHg can have a significant impact on the risk of cardiovascular complications, such as stroke and heart attack, but gain is greatest in those who are most at risk, such as patients who also have other risk factors for cardiovascular health such as diabetes. Early blood pressure control may also limit the vascular aging process and yet over half of patients worldwide are not even at the basic standard of control of 140/90mmHg. With guidelines now suggesting lower BP targets of 130/80 for many, new treatments in this space are welcome. Renal denervation is a recently approved tool to safely aid in blood pressure lowering throughout the 24-hour cycle and is independent of patient adherence to medication. The procedure shows an excellent safety profile and typically takes under an hour to perform, with lasting BP reductions demonstrated.”
Recor Medical – the manufacturer of the Paradise System – has been focused on developing and testing uRDN for the treatment of hypertension since 2009, and completed three independently powered, sham-controlled, randomized clinical trials, all which demonstrate the efficacy and safety of the Paradise System. Recor has also initiated the US Global Paradise System (GPS) Post-Approval Study to collect real-world clinical evidence with long-term follow-up in 1,000 patients with uncontrolled hypertension in the United States.
The Paradise uRDN system is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure. A physician will make a medical assessment to determine if a patient is a candidate for ultrasound renal denervation. The most common risks include pain, vascular access site complications and vasospasm. Full important risk information can be viewed here.
*Anatomies vary. See Paradise IFU for treatment strategies.
- Liu H et al.: Arm Position and Blood Pressure Readings. The ARMS Crossover Randomized Clinical Trial. JAMA Intern Med. 2024;184(12):1436-1442. doi:10.1001/jamainternmed.2024.5213
- https://newsroom.heart.org/news/high-blood-pressure-while-lying-down-linked-to-higher-risk-of-heart-health-complications
About Recor Medical, Inc.
Recor Medical, headquartered in Palo Alto, Calif., a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd., is a medical technology company focused on transforming the management of hypertension. Recor has pioneered the use of the Paradise Ultrasound Renal Denervation system for the treatment of hypertension. The Paradise uRDN system is an investigational device in Japan, is FDA approved in the United States, and bears the CE mark. Recor has reported positive outcomes in three independent, randomized, sham-controlled studies of the Paradise uRDN system in patients with mild-to-moderate and resistant hypertension. In addition, Recor is conducting the Global Paradise System (“GPS”) Registry in the European Union and the UK, and has initiated the US GPS post-approval study in the United States.
http://www.recormedical.com/
About Otsuka Medical Devices Co., Ltd.
Otsuka Medical Devices Co., Ltd. engages in the global development and commercialization of medical devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment. Otsuka Medical Devices is a subsidiary of Otsuka Holdings Co., Ltd. (www.otsuka.com/en), a global healthcare company listed on the Tokyo Stock Exchange (JP 4578).
https://www.omd.otsuka.com/en/
Media Contact
Lisa Owens
The Mullings Group
lowens@mullingsgroup.com
+1-210-601-6647
Attachments
- Paradise™ Ultrasound Renal Denervation (uRDN) system
- Ultrasound Renal Denervation with the Paradise System
CONTACT: Lara Barghout Recor Medical +1 650 542 7700 lara.barghout@recormedical.com
